Table 1 Baseline characteristics of CDSS art patients by site type, n = 5901
Characteristic | Control | Intervention | Total | P value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Unweighted n | Weighted % | 95% CI | Unweighted n | Weighted % | 95% CI | Unweighted N | Weighted % | 95% CI | ||
Age group, years | < .001 | |||||||||
< 10 years | 303 | 8.4 | (7.5–9.3) | 170 | 7.4 | (6.3–8.4) | 473 | 8 | (7.3–8.7) | |
10–19 years | 128 | 3.6 | (3.0–4.2) | 82 | 3.6 | (2.8–4.3) | 210 | 3.6 | (3.1–4.0) | |
20–29 years | 1065 | 29.6 | (28.1–31.1) | 638 | 27.7 | (25.8–29.5) | 1703 | 28.9 | (27.7–30.0) | |
30–39 years | 1169 | 32.5 | (31.0–34.0) | 766 | 33.2 | (31.3–35.1) | 1935 | 32.8 | (31.6–34.0) | |
40–49 years | 610 | 17 | (15.7–18.2) | 359 | 15.6 | (14.1–17.0) | 969 | 16.4 | (15.5–17.4) | |
50–59 years | 251 | 7 | (6.1–7.8) | 210 | 9.1 | (7.9–10.3) | 461 | 7.8 | (7.1–8.5) | |
60 + years | 69 | 1.9 | (1.5–2.4) | 81 | 3.5 | (2.8–4.3) | 150 | 2.5 | (2.1–2.9) | |
Total | 3595 | 100 | (–) | 2306 | 100 | (–) | 5901 | 100 | (–) | |
Sex | 0.055 | |||||||||
Male | 1311 | 36.5 | (34.9–38.0) | 898 | 38.9 | (37.0–40.9) | 2209 | 37.4 | (36.2–38.7) | |
Female | 2284 | 63.5 | (62.0–65.1) | 1408 | 61.1 | (59.1–63.0) | 3692 | 62.6 | (61.3–63.8) | |
Total | 3595 | 100 | (–) | 2306 | 100 | (–) | 5901 | 100 | (–) | |
Marital status | < .001 | |||||||||
Missing | 309 | 8.6 | (7.7–9.5) | 202 | 8.8 | (7.6–9.9) | 511 | 8.7 | (7.9–9.4) | |
Married | 1934 | 53.8 | (52.2–55.4) | 1163 | 50.4 | (48.4–52.5) | 3097 | 52.5 | (51.2–53.8) | |
Divorced/separated | 138 | 3.8 | (3.2–4.5) | 133 | 5.8 | (4.8–6.7) | 271 | 4.6 | (4.1–5.1) | |
Widow | 673 | 18.7 | (17.4–20.0) | 401 | 17.4 | (15.8–18.9) | 1074 | 18.2 | (17.2–19.2) | |
Single | 541 | 15 | (13.9–16.2) | 407 | 17.6 | (16.1–19.2) | 948 | 16.1 | (15.1–17.0) | |
Total | 3595 | 100 | (–) | 2306 | 100 | (–) | 5901 | 100 | (–) | |
CD4 category | < .001 | |||||||||
Missing | 846 | 23.5 | (22.1–24.9) | 727 | 31.5 | (29.6–33.4) | 1573 | 26.7 | (25.5–27.8) | |
< 200 | 1592 | 44.3 | (42.7–45.9) | 900 | 39 | (37.0–41.0) | 2492 | 42.2 | (41.0–43.5) | |
200–349 | 984 | 27.4 | (25.9–28.8) | 620 | 26.9 | (25.1–28.7) | 1604 | 27.2 | (26.0–28.3) | |
350–500 | 78 | 2.2 | (1.7–2.6) | 33 | 1.4 | (0.9–1.9) | 111 | 1.9 | (1.5–2.2) | |
≥ 500 | 95 | 2.6 | (2.1–3.2) | 26 | 1.1 | (0.7–1.6) | 121 | 2.1 | (1.7–2.4) | |
Total | 3595 | 100 | (–) | 2306 | 100 | (–) | 5901 | 100 | (–) | |
WHO stage | 0.105 | |||||||||
Missing | 193 | 5.4 | (4.6–6.1) | 105 | 4.6 | (3.7–5.4) | 298 | 5 | (4.5–5.6) | |
WHO I | 707 | 19.7 | (18.4–21.0) | 487 | 21.1 | (19.5–22.8) | 1194 | 20.2 | (19.2–21.3) | |
WHO II | 1056 | 29.4 | (27.9–30.9) | 645 | 28 | (26.1–29.8) | 1701 | 28.8 | (27.7–30.0) | |
WHO III | 1550 | 43.1 | (41.5–44.7) | 993 | 43.1 | (41.0–45.1) | 2543 | 43.1 | (41.8–44.4) | |
WHO IV | 89 | 2.5 | (2.0–3.0) | 76 | 3.3 | (2.6–4.0) | 165 | 2.8 | (2.4–3.2) | |
Total | 3595 | 100 | (–) | 2306 | 100 | (–) | 5901 | 100 | (–) | |
First line regimen | < .001 | |||||||||
Nevirapine | 3084 | 85.8 | (84.6–86.9) | 1803 | 78.2 | (76.5–79.9) | 4887 | 82.8 | (81.9–83.8) | |
Efavirenz | 489 | 13.6 | (12.5–14.7) | 465 | 20.2 | (18.5–21.8) | 954 | 16.2 | (15.2–17.1) | |
Other | 22 | 0.6 | (0.4–0.9) | 38 | 1.6 | (1.1–2.2) | 60 | 1 | (0.8–1.3) | |
Total | 3595 | 100 | (–) | 2306 | 100 | (–) | 5901 | 100 | (–) | |
Art adherence | 0.012 | |||||||||
Missing | 3112 | 86.6 | (85.4–87.7) | 1934 | 83.9 | (82.4–85.4) | 5046 | 85.5 | (84.6–86.4) | |
Satisfactory | 480 | 13.4 | (12.2–14.5) | 368 | 16 | (14.5–17.5) | 848 | 14.4 | (13.5–15.3) | |
Unsatisfactory | 3 | 0.1 | (0.0–0.2) | 4 | 0.2 | (0.0–0.3) | 7 | 0.1 | (0.0–0.2) | |
Total | 3595 | 100 | (–) | 2306 | 100 | (–) | 5901 | 100 | (–) | |